Harvard Bioscience (HBIO) EV to EBITDA (2010 - 2026)

Harvard Bioscience (HBIO) has reported EV to EBITDA for 17 consecutive years, with 21.98 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 48.12% year-over-year to 21.98 in Q2 2026; TTM through Jun 2026 was 87.73, a 37694.03% decrease from a year earlier, with the FY2025 full-year figure at 0.44, up 96.93% from the prior year.
• EV to EBITDA was 21.98 for Q2 2026 at Harvard Bioscience, down from 12.66 in the prior quarter.
• Over five years, EV to EBITDA peaked at 8080.83 in Q4 2024 and troughed at 245.2 in Q4 2022.
• A 5-year average of 480.18 and a median of 13.75 in 2025 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA jumped 900.01% in 2024 and tumbled 3099.84% in 2026, its largest moves.
• Over 5 years, EV to EBITDA stood at 245.2 in 2022, then soared by 429.55% to 808.08 in 2023, then soared by 900.01% to 8080.83 in 2024, then slumped by 99.85% to 12.48 in 2025, then plunged by 276.04% to 21.98 in 2026.
• The last three EV to EBITDA figures came in at 21.98 (Q2 2026), 12.66 (Q1 2026), and 12.48 (Q4 2025), per Business Quant data.